Anzeige
Mehr »
Login
Donnerstag, 18.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Kurze Gold-Preis-Konsolidierung zum Einstieg in diese Aktie nutzen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PYWE | ISIN: US03969K1088 | Ticker-Symbol:
NASDAQ
17.04.24
21:59 Uhr
10,230 US-Dollar
0,000
0,00 %
1-Jahres-Chart
ARCUTIS BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ARCUTIS BIOTHERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur ARCUTIS BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrEvaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts7
10.04.Arcutis Biotherapeutics, Inc. - 8-K, Current Report3
10.04.Arcutis Biotherapeutics Appoints David Topper To Succeed John Smither As CFO2
10.04.Arcutis Biotherapeutics appoints CFO1
10.04.Arcutis Biotherapeutics, Inc.: Arcutis Appoints David Topper as Chief Financial Officer368WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology...
► Artikel lesen
05.04.Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)107WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...
► Artikel lesen
10.03.Arcutis Biotherapeutics, Inc.: Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting148Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 139.4% of children...
► Artikel lesen
09.03.Arcutis Biotherapeutics, Inc.: New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction97Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signatureSuggests skin barrier disruption in seborrheic dermatitis is distinct with its own disease-specific...
► Artikel lesen
04.03.Arcutis Biotherapeutics, Inc.: Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares6
01.03.Earnings call: Arcutis outlines strong Q4, eyes expansion in 202413
29.02.Arcutis Biotherapeutics, Inc.: Arcutis to Present at the TD Cowen 44th Annual Health Care Conference4
29.02.Arcutis Biotherapeutics drops on $150 million stock deal5
29.02.Arcutis announces pricing of $150 million public offering1
29.02.Arcutis announces $150 million public stock offering3
29.02.Arcutis Biotherapeutics, Inc.: Arcutis Announces Pricing of $150 Million Public Offering2
29.02.Arcutis stock target raised to $11 on strong sales2
28.02.Arcutis Biotherapeutics launches $150 million public offering3
28.02.Arcutis secures Japan deal for skin treatment roflumilast2
28.02.Arcutis Biotherapeutics, Inc.: Arcutis Announces Proposed Public Offering1
28.02.Arcutis Biotherapeutics, Inc.: Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan225Arcutis to receive a $25 million upfront payment, and is eligible to receive potential development and commercial milestone payments (totaling $40 million), as well as tiered, double-digit royaltiesAgreement...
► Artikel lesen
Seite:  Weiter >>
75 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2